Investor Type | Firm |
Type of Fund | VC |
Industries | BioTech • FinTech (& Financials services) • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Pharmaceutical (& Medicine) |
Stages | Seed, Series A, Series B |
Investing | United States • Canada • China • Hong Kong • Israel |
Investment Range | $1,000,000 - $75,000,000 |
Investment Sweet Spot | $4,000,000 |
Assets Under Management | $18,000,000,000 |
OrbiMed is a healthcare-focused venture capital and private equity firm with a comprehensive investment approach spanning the entire healthcare sector, including biopharmaceuticals, medical devices, diagnostics, healthcare technology, and healthcare services. Founded in 1989 and headquartered in New York, OrbiMed manages approximately $18 billion in assets across a range of funds, utilizing their global team of experienced investment professionals and their extensive network within the healthcare community to identify and support innovative companies. Their portfolio ranges from start-ups to large multinational entities. With a focus on both private and public equity markets, OrbiMed provides funding for a wide array of investment stages, including seed, Series A, and Series B financing. They actively seek out promising opportunities in the pharmaceutical, life science, digital health, and biotechnology sectors, as well as in other related fields, with a preference for groundbreaking and high-impact advancements in healthcare. The firm is known for its integrity, diligence, collaboration, and its commitment to advancing the cause of health and wellness globally. OrbiMed's approach to investing is characterized by deep due diligence, active board participation, and a long-term horizon to support companies throughout their growth phases. They typically invest between $1 million and $75 million in their portfolio companies, with a sweet spot of around $4 million. As part of their support structure, OrbiMed leverages its internal resources, including scientific advisory boards and global healthcare sector expertise, to provide tangible strategic advantages to its portfolio companies.